Precipio (NASDAQ:PRPO) and closely-held H3 Biomedicine began a second development project to create a targeted gene panel that H3 will use in its ongoing clinical programs.
The panel will amplify targeted regions of genes that H3 is studying as part of its genomics-driven cancer drug discovery strategy.
As with its first project with H3, Precipio will develop multiplexed PCR assays for gene variants implicated in various cancers, and will develop nine amplicons with which to amplify and multiplex mutations of interest.
“This is one of many projects in our pipeline that demonstrates Precipio’s value to pharma and biotech companies as they take their research from the bench to the clinical setting,” Stephen Miller, Precipio’s chief commercial officer, said in a statement.
H3 is a research and development subsidiary of Eisai, and currently has three candidates in Phase 1 of development.
